The FDA Has Cleared Tango Therapeutics' Investigational New Drug Application For TNG348 For BRCA 1/2 Mutant And Other HRD+ (Homologous Recombination Deficient) Cancers
Portfolio Pulse from Benzinga Newsdesk
The FDA has cleared Tango Therapeutics' Investigational New Drug Application for TNG348, a treatment for BRCA 1/2 mutant and other HRD+ cancers.
September 06, 2023 | 11:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tango Therapeutics' TNG348 has received FDA clearance, potentially boosting the company's stock in the short term.
The FDA clearance of Tango Therapeutics' Investigational New Drug Application for TNG348 is a significant regulatory milestone for the company. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100